Health X Platform members approve composite scheme at 37th AGM

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Members approved a composite scheme of arrangement involving four entities including Microsec Resources and Innogrow Technologies.
  • Financial statements for FY26 were adopted without any qualifications in auditor reports.
  • Mrs. Anjana Dikshit was re-appointed as an Independent Director for a second five-year term.
  • Special resolutions authorized borrowing limits, asset mortgages, and related-party transactions.
powered bylight_fuzz_icon
52156670

*this image is generated using AI for illustrative purposes only.

Health X Platform Limited, formerly known as Sastasundar Ventures Limited, concluded its 37th Annual General Meeting on September 28, 2026. The meeting was conducted via Video Conferencing and Other Audio Visual Means, with 104 members participating in the proceedings.

The primary focus of the meeting was the approval of a Composite Scheme of Arrangement and Amalgamation. This strategic restructuring involves Health X Platform, Microsec Resources Private Limited, Innogrow Technologies Limited, and Sastasundar Healthbuddy Limited. The scheme aims to consolidate digital healthcare assets under a unified corporate structure.

Strategic Digital Assets Highlighted

During the address, Chairman B. L. Mittal emphasized the company's strengthened position through its key digital platforms. The company outlined its portfolio of digitally driven services designed to enhance healthcare access and supply chain efficiency:

  • SastaSundar App: A consumer-centric platform for seamless healthcare access.
  • RetailerShakti App: A B2B supply chain solution empowering pharmacies.
  • JitoHealth.com: A platform promoting generic medicines with AI-driven recommendations.
  • SastaSundar Health & Happiness Podcast: An initiative to combat misinformation with trusted information.

Composite Scheme Details

The Board approved the composite scheme on June 10, 2026, following recommendations from the Committee of Independent Directors and the Audit Committee. The arrangement is subject to approvals from stock exchanges, SEBI, NCLT, RBI, and respective shareholders and creditors. NOC applications have been filed with the stock exchanges and RBI.

Resolutions Passed

Members transacted both ordinary and special business items as per the notice dated August 7, 2026. Key resolutions included the adoption of audited financial statements for FY26 and various borrowing authorizations.

Resolution Type Item Status
Ordinary Adopt Audited Financial Statements (Standalone & Consolidated) for FY26 Passed
Ordinary Re-appointment of Mrs. Abha Mittal (retiring by rotation) Passed
Special Re-appointment of Mrs. Anjana Dikshit as Independent Director (5 years) Passed
Special Approve overall borrowing limit under Section 180(1)(c) Passed
Special Authorize creation of mortgage or charge on assets Passed
Special Authorize loans, guarantees, security, and investments Passed
Special Authorize loans/guarantees/security under Section 185 Passed

Governance and Compliance

The meeting was chaired by Mr. B. L. Mittal, with all directors and key managerial personnel present. The statutory auditors' report contained no qualifications, reservations, or adverse remarks. Similarly, the secretarial audit report was clean. Voting results will be disclosed to stock exchanges and company websites within two working days.

Historical Stock Returns for Health X Platform

1 Day5 Days1 Month6 Months1 Year5 Years
-1.21%-4.95%-3.88%+2.74%-8.11%0.0%

What is the expected timeline for NCLT and SEBI approvals for the Composite Scheme of Arrangement?

How will the consolidation of digital healthcare assets impact Health X Platform's competitive positioning against other Indian health-tech startups?

What specific revenue synergies are projected from integrating Microsec Resources and Innogrow Technologies into the unified structure?

Health X Platform files FY26 BRSR with BSE and NSE exchanges

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Health X Platform filed its FY26 BRSR with BSE and NSE on September 4, 2026
  • Paid-up capital stands at ₹3181.05 lakhs with consolidated reporting basis
  • Wholesale pharmaceutical trading contributes 98.80% of total turnover
  • No assurance provider was engaged for the sustainability report
powered bylight_fuzz_icon
50062349

*this image is generated using AI for illustrative purposes only.

Health X Platform Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 to the Bombay Stock Exchange and National Stock Exchange on September 4, 2026. The filing provides consolidated disclosures on the company’s operational and sustainability metrics.

The report was filed pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is also available on the company’s website. Pratap Singh, Company Secretary and Compliance Officer, signed the document.

General Disclosures

The listed entity, formerly known as Sastasundar Ventures Limited, was incorporated on June 6, 1989. Its registered and corporate office is located in Kolkata. The paid-up capital stands at ₹3181.05 lakhs. The reporting boundary for this BRSR is on a consolidated basis. No assurance provider was engaged for this report.

Detail Information
CIN L65993WB1989PLC047002
Paid-up Capital ₹3181.05 lakhs
Reporting Basis Consolidated
Assurance Provider Not Applicable

Business Activities

Wholesale trading of pharmaceutical and OTC products accounts for 98.80% of the entity’s turnover. Other financial service activities contribute a negligible 0.002%. The company operates under NIC codes 46497 and 46901 for its primary wholesale activities.

Activity % of Turnover
Wholesale of pharmaceutical/medical goods 98.80%
Other Financial Service activities 0.002%

Historical Stock Returns for Health X Platform

1 Day5 Days1 Month6 Months1 Year5 Years
-1.21%-4.95%-3.88%+2.74%-8.11%0.0%

How might the lack of an independent assurance provider for this BRSR impact investor confidence in Health X's sustainability claims compared to peers?

Given that 98.8% of turnover comes from pharmaceutical wholesale, what specific sustainability risks related to supply chain logistics or regulatory compliance is the company prioritizing in FY27?

Will Health X Platform initiate a strategic pivot to diversify its revenue streams beyond wholesale trading to mitigate concentration risk in the coming fiscal years?

More News on Health X Platform

1 Year Returns:-8.11%